Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 11/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842209 | 0.83 | CA1 (0.58) | PRKCIAKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL20630760 | 0.82 | PRKCI (0.69) | PRKCIAKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL9624564 | 0.79 | SMN1; SMN2 (0.53) | PRKCIAKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL28385567 | 0.78 | PRKCI (0.65) | PRKCIAKR1C3AKR1C2ALDH1A1AKR1B10 | |
| SCHEMBL1108312 | 0.78 | PRKCI (0.65) | PRKCIAKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL15075228 | 0.78 | PRKCI (0.65) | PRKCIAKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL3022646 | 0.77 | MAPT (0.47) | PRKCIAKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL16281303 | 0.77 | PRKCI (0.62) | PRKCIAKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL2245773 | 0.77 | PRKCI (1.00) | PRKCIAKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL913429 | 0.76 | L3MBTL1 (0.46) | PRKCIAKR1C3AKR1C2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2808020-A1 | Beta-Amyloid Pet Imaging Agents | The Government Of The United States, As Represented by The Secretary Of Health And Human Services (US) | 2014-12-03 | — | — | EP | disclosed |
| EP-2808020-A1 | Beta-Amyloid Pet Imaging Agents | The Government Of The United States, As Represented by The Secretary Of Health And Human Services (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2021340-B1 | BETA-AMYLOID PET IMAGING AGENTS | US GOVERNMENT (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2021340-B1 | BETA-AMYLOID PET IMAGING AGENTS | US GOVERNMENT (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8703096-B2 | Beta-amyloid PET imaging agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703096-B2 | Beta-amyloid PET imaging agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2021340-A2 | BETA-AMYLOID PET IMAGING AGENTS | The Government Of The United States, As Represented by The Secretary Of Health And Human Services (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007124345-A2 | BETA-AMYLOID PET IMAGING AGENTS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | APP, BACE1, PSEN1 | PRKCI 3954/4885AKR1C3 4382/4885AKR1C2 4391/4885 |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | APP, BACE1, PSEN1 | PRKCI 3954/4885AKR1C3 4382/4885AKR1C2 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.